riluzole has been researched along with Degenerative Diseases, Central Nervous System in 11 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease commonly treated with riluzole, a small molecule that may act via modulation of glutamatergic neurotransmission." | 8.02 | Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis. ( Atkin, JD; Berning, BA; Blizzard, CA; Chung, RS; Della Gatta, PA; Gul, H; Hedl, TJ; Jacobs, KR; Keating, SS; Le, S; Lee, A; Mehta, P; Morsch, M; Riddell, WR; San Gil, R; Shi, B; Venturato, J; Walker, AK; Watson, O; Wright, AL, 2021) |
| "Riluzole is an antiglutamatergic agent and the only drug to offer some effect on the life expectancy of ALS patients." | 5.46 | Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam. ( Andreasen, SR; Christensen, TB; Holm, MM; Lundbye, CJ; Schmitt-John, T; Thielsen, KD, 2017) |
| " Riluzole is the only drug approved by the US Food and Drug Administration for amyotrophic lateral sclerosis." | 4.98 | The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis. ( Liu, J; Wang, LN, 2018) |
| "Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease commonly treated with riluzole, a small molecule that may act via modulation of glutamatergic neurotransmission." | 4.02 | Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis. ( Atkin, JD; Berning, BA; Blizzard, CA; Chung, RS; Della Gatta, PA; Gul, H; Hedl, TJ; Jacobs, KR; Keating, SS; Le, S; Lee, A; Mehta, P; Morsch, M; Riddell, WR; San Gil, R; Shi, B; Venturato, J; Walker, AK; Watson, O; Wright, AL, 2021) |
| " Riluzole is used for the treatment of amyotrophic lateral sclerosis and reported to have neuroprotective effects in animal models of Parkinson's disease, Huntington's disease, and brain ischemia." | 3.72 | Riluzole enhances glutamate uptake in rat astrocyte cultures. ( Dalcin, KB; Dall'Onder, LP; Frizzo, ME; Souza, DO, 2004) |
| "Amyotrophic Lateral Sclerosis is a neurodegenerative disease caused by progressive loss of motor neurons, which severely compromises skeletal muscle function." | 2.82 | Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle. ( Camerino, GM; Canfora, I; Pierno, S; Tarantino, N, 2022) |
| "Riluzole is an antiglutamatergic agent and the only drug to offer some effect on the life expectancy of ALS patients." | 1.46 | Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam. ( Andreasen, SR; Christensen, TB; Holm, MM; Lundbye, CJ; Schmitt-John, T; Thielsen, KD, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Tarantino, N | 1 |
| Canfora, I | 1 |
| Camerino, GM | 1 |
| Pierno, S | 1 |
| Wong, C | 1 |
| Dakin, RS | 1 |
| Williamson, J | 1 |
| Newton, J | 1 |
| Steven, M | 1 |
| Colville, S | 1 |
| Stavrou, M | 1 |
| Gregory, JM | 1 |
| Elliott, E | 1 |
| Mehta, AR | 1 |
| Chataway, J | 1 |
| Swingler, RJ | 1 |
| Parker, RA | 1 |
| Weir, CJ | 1 |
| Stallard, N | 1 |
| Parmar, MKB | 1 |
| Macleod, MR | 1 |
| Pal, S | 1 |
| Chandran, S | 1 |
| Pinard, M | 3 |
| Dastpeyman, S | 3 |
| Poitras, C | 3 |
| Bernard, G | 3 |
| Gauthier, MS | 3 |
| Coulombe, B | 3 |
| Wright, AL | 1 |
| Della Gatta, PA | 1 |
| Le, S | 1 |
| Berning, BA | 1 |
| Mehta, P | 1 |
| Jacobs, KR | 1 |
| Gul, H | 1 |
| San Gil, R | 1 |
| Hedl, TJ | 1 |
| Riddell, WR | 1 |
| Watson, O | 1 |
| Keating, SS | 1 |
| Venturato, J | 1 |
| Chung, RS | 1 |
| Atkin, JD | 1 |
| Lee, A | 1 |
| Shi, B | 1 |
| Blizzard, CA | 1 |
| Morsch, M | 1 |
| Walker, AK | 1 |
| Andreasen, SR | 1 |
| Lundbye, CJ | 1 |
| Christensen, TB | 1 |
| Thielsen, KD | 1 |
| Schmitt-John, T | 1 |
| Holm, MM | 1 |
| Liu, J | 1 |
| Wang, LN | 1 |
| Yang, J | 1 |
| Bridges, K | 1 |
| Chen, KY | 1 |
| Liu, AY | 1 |
| Cifra, A | 1 |
| Nani, F | 1 |
| Sharifullina, E | 1 |
| Nistri, A | 1 |
| Sanacora, G | 1 |
| Frizzo, ME | 1 |
| Dall'Onder, LP | 1 |
| Dalcin, KB | 1 |
| Souza, DO | 1 |
| Fumagalli, E | 1 |
| Bigini, P | 1 |
| Barbera, S | 1 |
| De Paola, M | 1 |
| Mennini, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial[NCT04302870] | Phase 2/Phase 3 | 800 participants (Anticipated) | Interventional | 2020-02-27 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for riluzole and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle.
Topics: Amyotrophic Lateral Sclerosis; Humans; Ion Channels; Muscle, Skeletal; Neurodegenerative Diseases; R | 2022 |
The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.
Topics: Amyotrophic Lateral Sclerosis; Humans; Neurodegenerative Diseases; Neuroprotective Agents; Randomize | 2018 |
Do glutamatergic agents represent a new class of antidepressant drugs? Part 1.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Drug Design; Hum | 2009 |
1 trial available for riluzole and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Memantine; Motor Neuron Disease; Neurode | 2022 |
7 other studies available for riluzole and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Riluzole partially restores RNA polymerase III complex assembly in cells expressing the leukodystrophy-causative variant POLR3B R103H.
Topics: DNA-Directed RNA Polymerases; Humans; Mutation, Missense; Neurodegenerative Diseases; Riluzole; RNA | 2022 |
Riluzole partially restores RNA polymerase III complex assembly in cells expressing the leukodystrophy-causative variant POLR3B R103H.
Topics: DNA-Directed RNA Polymerases; Humans; Mutation, Missense; Neurodegenerative Diseases; Riluzole; RNA | 2022 |
Riluzole partially restores RNA polymerase III complex assembly in cells expressing the leukodystrophy-causative variant POLR3B R103H.
Topics: DNA-Directed RNA Polymerases; Humans; Mutation, Missense; Neurodegenerative Diseases; Riluzole; RNA | 2022 |
Riluzole partially restores RNA polymerase III complex assembly in cells expressing the leukodystrophy-causative variant POLR3B R103H.
Topics: DNA-Directed RNA Polymerases; Humans; Mutation, Missense; Neurodegenerative Diseases; Riluzole; RNA | 2022 |
Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; DNA-Binding Proteins; Female; Mice; | 2021 |
Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam.
Topics: Amyotrophic Lateral Sclerosis; Animals; Diazepam; Disease Models, Animal; Hippocampus; Mice, Inbred | 2017 |
Riluzole increases the amount of latent HSF1 for an amplified heat shock response and cytoprotection.
Topics: Cell Survival; DNA-Binding Proteins; Excitatory Amino Acid Agonists; Genes, Reporter; Heat Shock Tra | 2008 |
A repertoire of rhythmic bursting produced by hypoglossal motoneurons in physiological and pathological conditions.
Topics: Action Potentials; Animals; Brain Stem; Glutamic Acid; Humans; Hydrogen Peroxide; Hypoglossal Nerve; | 2009 |
Riluzole enhances glutamate uptake in rat astrocyte cultures.
Topics: Animals; Animals, Newborn; Astrocytes; Brain Ischemia; Cells, Cultured; Dose-Response Relationship, | 2004 |
Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease.
Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; CD11b Antigen; Cell Death; Choline O-Acetyl | 2006 |